Still Looking For A Cancer Vaccine Breakthrough, Roche Signs $200m Vaccibody Deal

Claims First Neoantigen Clinical Response In Advanced Cancer

 
• By Andrew McConaghie

Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.

Genetech
Genentech is forging ahead with neoantigen-targeting cancer vaccines, despite a recent disappointment with its BioNTech partnership

More from Business

More from Scrip